ATE482720T1 - Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen - Google Patents

Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen

Info

Publication number
ATE482720T1
ATE482720T1 AT03792365T AT03792365T ATE482720T1 AT E482720 T1 ATE482720 T1 AT E482720T1 AT 03792365 T AT03792365 T AT 03792365T AT 03792365 T AT03792365 T AT 03792365T AT E482720 T1 ATE482720 T1 AT E482720T1
Authority
AT
Austria
Prior art keywords
cell lysates
tumor cell
induced tumor
lysate
producing temperature
Prior art date
Application number
AT03792365T
Other languages
English (en)
Inventor
Steffen Goletz
Hans Baumeister
Ute Schoeber
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Application granted granted Critical
Publication of ATE482720T1 publication Critical patent/ATE482720T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT03792365T 2002-08-16 2003-08-18 Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen ATE482720T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018512 2002-08-16
PCT/EP2003/009140 WO2004018659A1 (en) 2002-08-16 2003-08-18 Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds

Publications (1)

Publication Number Publication Date
ATE482720T1 true ATE482720T1 (de) 2010-10-15

Family

ID=31896837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792365T ATE482720T1 (de) 2002-08-16 2003-08-18 Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen

Country Status (9)

Country Link
US (1) US7595192B2 (de)
EP (1) EP1530628B1 (de)
AT (1) ATE482720T1 (de)
AU (1) AU2003260426A1 (de)
DE (1) DE60334382D1 (de)
DK (1) DK1530628T3 (de)
ES (1) ES2353753T3 (de)
SI (1) SI1530628T1 (de)
WO (1) WO2004018659A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2353753T3 (es) 2002-08-16 2011-03-04 Glycotope Gmbh Procedimiento para la producción de lisados de células tumorales inducidas por temperatura para usar como compuestos inmunógenos.
US8017388B2 (en) * 2003-08-18 2011-09-13 Glycotope Gmbh Tumour cell lines and uses thereof
JP4913604B2 (ja) * 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
WO2007001200A1 (en) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Mature dendritic cells loaded with tumor polylysates and antitumoral vaccine base thereon
GB0601598D0 (en) * 2006-01-26 2006-03-08 Stathopoulos Apostolos Method
DK2073842T4 (da) 2006-09-10 2024-01-15 Glycotope Gmbh Anvendelse af humane celler af myloid leukæmioprindelse til udtrykkelse af anti-stoffer
EP1920781B1 (de) 2006-11-10 2015-03-04 Glycotope GmbH Zusammensetzungen die ein Core-1 positives Mikroorganismus enthalten und deren Verwendung zur Behandlung von Tumoren
CL2007002825A1 (es) * 2007-09-28 2008-05-30 Univ De Chile Oncobiomed Metodo para generar vacunas que estimulen el sistema inmune que comprende inducir celulas mononucleares de sangre periferica a que se diferencien a apc, para luego, separar dichas apc y mezclarlas con adyuvantes; extracto de celulas tumorales; y comp
EP2281844A1 (de) 2009-07-31 2011-02-09 Glycotope GmbH MUC-1-Antikörper
RU2014110953A (ru) 2011-08-22 2015-09-27 Гликотоп Гмбх Микроорганизмы, несущие опухолевый антиген
CN103800896A (zh) * 2012-11-15 2014-05-21 厦门鹭佳生物科技有限公司 一种自体肿瘤疫苗的制备方法及其应用
CA2896994A1 (en) * 2012-12-28 2014-07-03 Amphera B.V. Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells
SMT202300227T1 (it) 2018-05-18 2023-09-06 Glycotope Gmbh Anticorpo anti-muc1
EP4003424A4 (de) * 2019-07-22 2023-11-22 Todd Alamin Zellbehandlungen und therapeutische reinfusionsverfahren
WO2024026505A2 (en) * 2022-07-29 2024-02-01 Amit Patel Disruption of telocyte activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
EP0702722B1 (de) 1993-06-07 2005-08-03 Vical Incorporated Für die gentherapie verwendbare plasmide
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
WO1997040182A1 (de) 1996-04-19 1997-10-30 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
EP1216055A2 (de) * 1999-09-30 2002-06-26 Corixa Corporation Stress protein zusammensetzungen und verfahren zur vorbeugung ung behandlung von krebs und infektionskrankheiten
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
WO2004009632A2 (de) 2002-07-22 2004-01-29 Nemod Immuntherapie Ag Verfahren zur herstellung eines immunstimulatorischen muzins (muc1)
ES2353753T3 (es) 2002-08-16 2011-03-04 Glycotope Gmbh Procedimiento para la producción de lisados de células tumorales inducidas por temperatura para usar como compuestos inmunógenos.
US8017388B2 (en) 2003-08-18 2011-09-13 Glycotope Gmbh Tumour cell lines and uses thereof

Also Published As

Publication number Publication date
EP1530628A1 (de) 2005-05-18
WO2004018659A1 (en) 2004-03-04
US7595192B2 (en) 2009-09-29
DK1530628T3 (da) 2011-01-10
EP1530628B1 (de) 2010-09-29
DE60334382D1 (de) 2010-11-11
ES2353753T3 (es) 2011-03-04
US20060127419A1 (en) 2006-06-15
AU2003260426A1 (en) 2004-03-11
SI1530628T1 (sl) 2011-02-28

Similar Documents

Publication Publication Date Title
DE60334382D1 (de) Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
MY209387A (en) Multi-specific binding proteins for cancer treatment
IL208795A0 (en) Multispecific deimmunized cd3-binders
MX2021013219A (es) Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos.
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
WO2014028453A3 (en) Natural killer cells and uses thereof
SG146682A1 (en) Modulation of eif4e expression
MX363423B (es) Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
JP2020511131A5 (de)
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
ATE517633T1 (de) Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine
RU2013111675A (ru) Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc
WO2009062260A8 (en) Therapy for multiple sclerosis
MX2024003615A (es) Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3).
BRPI0610968A2 (pt) composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação
RU2008130457A (ru) Опухолевая вакцина, содержащая аллогенные или ксеногенные опухолевые клетки
DE60331228D1 (de) Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen
WO2005018540A3 (en) Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
WO2025010341A3 (en) Cytokine hybrid proteins and methods related thereto
MY160857A (en) A cancer vaccine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1530628

Country of ref document: EP